Relmada Therapeutics (RLMD) Finished Goods (2012 - 2013)
Relmada Therapeutics (RLMD) reported Finished Goods of $4734.0 for Q4 2013, up 49.38% on a QoQ basis from $3169.0 in Q3 2013.
Relmada Therapeutics (RLMD) has 2 years of Finished Goods data on file, last reported at $4734.0 in Q4 2013.
- Quarterly Finished Goods changed N/A year-over-year to $4734.0 in Q4 2013, while the trailing twelve-month figure through Nov 2013 was $4734.0 (changed N/A YoY) and the FY2013 annual result came in at $3169.0, down 50.52% from the prior year.
- Finished Goods climbed to $4734.0 in Q4 2013 per RLMD's latest filing, from $3169.0 in the prior quarter.
- Across five years, Finished Goods topped out at $6405.0 in Q3 2012 and bottomed at $2369.0 in Q2 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | 4,734.00 |
| Aug 31, 2013 | 3,169.00 |
| May 31, 2013 | 2,369.00 |
| Feb 28, 2013 | 2,690.00 |
| Aug 31, 2012 | 6,405.00 |